Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma

Donato Rigante, Ida Orlando, Antonio Vitale, Giuseppe Lopalco, Claudia Fabiani, Luca Cantarini

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The authors describe a patient with Behçet's disease treated with anakinra and canakinumab after bladder papillary cancer excision. The same patient had been previously proven to be unresponsive to standard therapy, including TNF-α inhibitors.
Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalInternal Medicine Journal
Volume2017
DOIs
Publication statusPublished - 2017

Keywords

  • Behçet's disease

Fingerprint

Dive into the research topics of 'Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma'. Together they form a unique fingerprint.

Cite this